News Medical1h
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Zacks.com on MSN9h
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Business Wire2d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Times West Virginian2dOpinion
Biden-Harris admin must act to ensure equitable access to HIV prevention drugs
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...